Document text
Pneumococcal Vaccines
Katherine A. Poehling, MD, MPH
Pneumococcal Vaccines Work Group Chair
Advisory Committee on Immunization Practices
February 22, 2023
Pneumococcal Vaccines Work Group
ACIP Members
• Katherine Poehling (Chair)
• Sarah Long
Ex Officio Members • Jeffrey Kelman (CMS)
• Lucia Lee (FDA)
• Tina Mongeau (FDA)
• Uzo Chukwuma (IHS)
• Mamodikoe Makhene (NIH)
CDC Lead
• Miwako Kobayashi (NCIRD) Liaison Representatives and Consultants
• Lynn Fisher (AAFP)
• Mark Sawyer (AAP/COID)
• Jason Goldman (ACP)
• David Nace (AGS/AMDA)
• Aleksandra Wierzbowski (NACI)
• James McAuley (IDSA)
• William Schaffner (NFID)
• Virginia Caine (NMA)
• Monica Farley (VAMC/Emory)
• Keith Klugman (BMGF)
• Arthur Reingold (UC Berkley)
• Lorry Rubin (CCMC)
• Richard Zimmerman (U. of Pittsburgh)
Pneumococcal Vaccines Work Group
CDC Contributors
• Adam Cohen (Respiratory Diseases Branch)
• Ryan Gierke (Respiratory Diseases Branch)
• Jennifer Farrar (Respiratory Diseases Branch)
• Pedro Moro (Immunization Safety Office)
• Liz Velazquez (Immunization Services Division)
• Marc Fischer (Arctic Investigations Program)
• Noele Nelson (Division of Bacterial Diseases)
• Jessica MacNeil (ACIP Secretariat)
GRADE/EtR consultants
• Doug Campos-Outcalt
• Rebecca Morgan
Pneumococcal vaccines currently recommended for
use in the United States
Recommended for
children Recommended for adults
Pneumococcal conjugate vaccines
PCV13
PCV15
PCV20
Pneumococcal polysaccharide vaccine PPSV23 Risk-based
recommendations If previously received PCV13 or PCV15
All children under age 2 years have the same
pneumococcal vaccine recommendations
• 3 primary series and a booster=“3+1” schedule
PCV PCV PCV PCV 2months 4months 12–15 months 6months
Primary Series Booster
Either PCV13 or PCV15 can be used for U.S. children.
Children with certain underlying conditions are recommended
to receive PPSV23 in addition to the recommended PCV doses
PPSV23 Recommended
PCV doses Recommended
PCV doses Healthy
children
CMC, CSF leak,
cochlear
implant
≥8 weeks
Recommended
PCV doses PPSV23 PPSV23 Immuno-
compromised
≥8 weeks ≥5 years
CMC aged 6–18
years PPSV23
Note: Excludes catch-up vaccination schedules.
CMC=chronic medical conditions, including chronic heart disease, chronic lung disease, diabetes mellitus
CSF=cerebrospinal fluid
Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization
Practices — United States, 2022 | MMWR (cdc.gov)
2022 2023 February 2023
Pediatric PCV20 use approval
anticipated Q2 2023
Pediatric PCV15 use
June 2022 approved Approval of PCV20 use among Children Anticipated in 2023
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal
Conjugate Vaccine in Infants and Children | Pfizer
Policy questions considered by the Work Group
• Should PCV20 be recommended as an option for pneumococcal
conjugate vaccination according to currently recommended dosing
and schedules, for U.S. children aged <2 years ?
• Should PCV20 without PPSV23 be recommended as an option for
pneumococcal vaccination for U.S. children aged 2–18 years with
underlying medical conditions that increase the risk of
pneumococcal disease?
Today’s Pneumococcal Vaccines session outline
Introduction Dr. Katherine Poehling
(ACIP , WG Chair)
Epidemiology of pneumococcal disease among U.S. children Mr. Ryan Gierke (CDC/NCIRD)
Pediatric outpatient ARI visits and antibioticattributable to serotypes in higher valency PCVs use Ms. Laura King (U.C. Berkeley)
PCV20 phase 2/3 study results among children Dr. Wendy Watson
(Pfizer)
Preliminary EtR for PCV20 use in U.S. children Dr. Miwako Kobayashi
(CDC/NCIRD)
Work Group considerations and next steps Dr. Miwako Kobayashi
(CDC/NCIRD)